ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q2 2020

Strong sales growth during Q2; Zinzino group revenue increased with a total of 53% in Q2 and 49% YTD, compared with the previous year.

The revenue in June for Zinzino's sales markets increased by 77% to MSEK 94.9 (53.7) primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 15% and amounted to MSEK 5.3 (4.6). Overall, the Group increased revenues by 72% to MSEK 100.2 (58.3) compared with the previous year.

The second quarter of 2020 became the strongest quarter in the history of the company. The Zinzino based revenue in April - June increased 57% MSEK 258.8 (165.2) compared with previous year. Total group revenue increased 53% to MSEK 274,8 (179,5).

Accumulated revenue for January – June 2020 increased by 49% MSEK 516.8 (347.8).

Revenues distributed as follows:

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12, marcus.tollbom@zinzino.com

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00,
email: certifiedadviser@penser.se

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 14:00 the 6th of July 2020.

Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the research unit BioActive Foods AS and production unit Faun Pharma AS. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Adelaide. Zinzino is a public company and its shares are listed on Nasdaq First North Growth Market.